Family · Pharmaceutical analytical standards
Acalabrutinib
A second-generation inhibitor of Bruton's tyrosine kinase (BTK), more selective than ibrutinib, approved in the United States in 2017 for mantle cell lymphoma, a cancer of B lymphocytes. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?The protein it blocks is named after paediatrician Ogden Bruton, who in 1952 described agammaglobulinaemia, the disease caused by a defect in the BTK gene itself.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
